GlassScriptPhysician profile
Mohammad Pashmforoush
NPI 1699722397
$17,070.77
in general payments reported to CMS, 2019-2025
43 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,398 · 2020: $3,536 · 2021: $2,467 · 2022: $1,799 · 2023: $1,672 · 2024: $1,681 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,775.21 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,632.98 | 2019-2025 | Ensite, Gallant, Tacticath Ablation Catheter, Sensor Enabled |
| Biotronik INC. | $2,445.31 | 2020-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Medical Device Business Services, INC. | $829.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $722.76 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $665.83 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $581.03 | 2023-2025 | Sapien 3 Ultra Resilia |
| Acutus Medical, INC. | $579.93 | 2020-2021 | |
| Boston Scientific Corporation | $396.59 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Kestra Medical Technology Services, INC. | $331.83 | 2022-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $314.78 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $300.59 | 2019-2025 | |
| Pfizer INC. | $268.16 | 2019-2025 | |
| Infobionic, INC | $226.51 | 2025 | Mome Device |
| Merck Sharp & Dohme LLC | $220.80 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $155.68 | 2021-2023 | Arcalyst |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Pashmforoush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.